Mammoth Biosciences Stock

mammoth.bioHealthcare / BioTech & PharmaFounded: 2017Funding to Date: $622.5MM

Mammoth Biosciences is a biotechnology company that, through the discovery and development of novel CRISPR systems, is enabling the full potential of its platform to improve lives by reading and writing the code of life. The company was founded by Trevor Martin Ph.D., Janice Chen Ph.D., Lucas Harrington, and Jennifer Doudna Ph.D. in 2017 and is headquartered in Brisbane, CA.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for Mammoth Biosciences, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Mammoth Biosciences Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Mammoth Biosciences Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
04/22/2024 Series D-2 $107.74MM $xx.xx $1.35B Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
8,008,750
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
09/09/2021 Series D $112.5MM $xx.xx $1.08B Decheng Capital, Foresite Capital, Greenspring Associates, Mayfield, Nfx, Plum Alley, Redmile Group, Senator Investment Group, Sixth Street
Price per Share
$xx.xx
Shares Outstanding
8,362,385
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Decheng Capital, Foresite Capital, Greenspring Associates, Mayfield, Nfx, Plum Alley, Redmile Group, Senator Investment Group, Sixth Street
09/09/2021 Series D-1 $37.5MM $xx.xx $1.08B Decheng Capital, Foresite Capital, Greenspring Associates, Mayfield, Nfx, Plum Alley, Redmile Group, Senator Investment Group, Sixth Street
Price per Share
$xx.xx
Shares Outstanding
2,787,461
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Decheng Capital, Foresite Capital, Greenspring Associates, Mayfield, Nfx, Plum Alley, Redmile Group, Senator Investment Group, Sixth Street
11/04/2020 Series C $44.36MM $xx.xx $278.7MM Nfx
Price per Share
$xx.xx
Shares Outstanding
10,279,365
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Nfx
11/04/2020 Series C-1 $747,767.27 $xx.xx $278.7MM Nfx
Price per Share
$xx.xx
Shares Outstanding
192,530
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Nfx
01/30/2020 Series B $36.77MM $xx.xx $144.13MM Amoon, Brook Byers, Decheng Capital, Mayfield, Nfx, Pacific 8, Plum Alley Investments, Vreily
Price per Share
$xx.xx
Shares Outstanding
13,631,447
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Amoon, Brook Byers, Decheng Capital, Mayfield, Nfx, Pacific 8, Plum Alley Investments, Vreily
01/30/2020 Series B-1 $7.41MM $xx.xx $144.13MM Amoon, Brook Byers, Decheng Capital, Mayfield, Nfx, Pacific 8, Plum Alley Investments, Vreily
Price per Share
$xx.xx
Shares Outstanding
3,052,521
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Amoon, Brook Byers, Decheng Capital, Mayfield, Nfx, Pacific 8, Plum Alley Investments, Vreily
08/08/2018 Series A $18.1MM $xx.xx $36.19MM Plum Alley Investments
Price per Share
$xx.xx
Shares Outstanding
18,051,205
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Plum Alley Investments

Mammoth Biosciences Investors Also Invested in These Private Companies

Leadership & Board

Leadership

Trevor Martin Ph.D
Co-Founder & Chief Executive Officer
Lucas Harrington
Co-Founder & Chief Scientific Officer
Jennifer Doudna Ph.D
Co-Founder & Chairman of Scientific Advisory Board
Janice Chen Ph.D
Co-Founder & Chief Technology Officer
Ted Tisch
Chief Agility Officer

Board

Dean Minor MD
Board Member
Maneesh Jain Ph.D
Board Member
Ursheet Parikh
Mayfield (Private Equity)
Victor Tong Jr.
Decheng Capital

Mammoth Biosciences stock FAQs

plusminus

Can you buy Mammoth Biosciences stock?

As Mammoth Biosciences is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Mammoth Biosciences, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy Mammoth Biosciences stock?

To invest in a private company like Mammoth Biosciences through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Mammoth Biosciences stock?

Yes, you may sell the Mammoth Biosciences stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Mammoth Biosciences stock?

If you hold private company shares of Mammoth Biosciences – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Mammoth Biosciences on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Mammoth Biosciences a public company?

No, Mammoth Biosciences is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Mammoth Biosciences’ stock price?

Mammoth Biosciences is a privately held company and therefore does not have a public stock price. However, you may access Mammoth Biosciences private market stock price with Forge Data.
plusminus

What is Mammoth Biosciences’ stock ticker symbol?

Mammoth Biosciences does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Mammoth Biosciences News and Media Highlights

Mammoth Biosciences Announces Appointment of Phil Tinmouth, Siang Chin to Key Leadership Roles

Mammoth Biosciences, Inc., a biotechnology company building the next generation of CRISPR products with a mission to cure and detect diseases, today announced the appointment of Phil Tinmouth as Chief Business Officer and Siang Chin as General Counsel.

CRISPR biotech company Mammoth Biosciences gains unicorn status

San Francisco-based Mammoth Biosciences has closed on a $150 million Series D led by Redmile Group, which now values the CRISPR biotech company at $1 billion, making it a new addition to the Crunchbase Unicorn Board.

Mammoth Biosciences’s CRISPR-based COVID-19 test receives NIH funding through RADx program – TechCrunch

CRISPR tech startup Mammoth Biosciences is among the companies that revealed backing from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx) program on Friday. Mammoth received a contract to scale up its CRISPR-based SARS-CoV-2 diagnostic test in order to help address …

Mammoth Biosciences partners with GSK to develop handheld CRISPR-based COVID-19 test – TechCrunch

California-based Mammoth Biosciences has signed a powerful partner for its development of a CRISPR-based test for COVID-19, which would aim to delivery accurate, fast results using a handheld, disposable testing platform. Mammoth Biosciences will be using its DETECTR platform to develop the test, w…
Browse Insights
Updated on: Dec 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.